These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. C3 glomerulopathy and current dilemmas. Ito N; Ohashi R; Nagata M Clin Exp Nephrol; 2017 Aug; 21(4):541-551. PubMed ID: 27878657 [TBL] [Abstract][Full Text] [Related]
4. Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents. Holle J; Berenberg-Goßler L; Wu K; Beringer O; Kropp F; Müller D; Thumfart J Pediatr Nephrol; 2018 Dec; 33(12):2289-2298. PubMed ID: 30238151 [TBL] [Abstract][Full Text] [Related]
5. Discontinuation of dialysis with eculizumab therapy in a pediatric patient with dense deposit disease. Tran CL; Sethi S; Murray D; Cramer CH; Sas DJ; Willrich M; Smith RJ; Fervenza FC Pediatr Nephrol; 2016 Apr; 31(4):683-7. PubMed ID: 26759144 [TBL] [Abstract][Full Text] [Related]
6. C3 glomerulopathy and eculizumab: a report on four paediatric cases. Lebreton C; Bacchetta J; Dijoud F; Bessenay L; Fremeaux-Bacchi V; Sellier-Leclerc AL Pediatr Nephrol; 2017 Jun; 32(6):1023-1028. PubMed ID: 28236143 [TBL] [Abstract][Full Text] [Related]
7. Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. Le Quintrec M; Lapeyraque AL; Lionet A; Sellier-Leclerc AL; Delmas Y; Baudouin V; Daugas E; Decramer S; Tricot L; Cailliez M; Dubot P; Servais A; Mourey-Epron C; Pourcine F; Loirat C; Frémeaux-Bacchi V; Fakhouri F Am J Kidney Dis; 2018 Jul; 72(1):84-92. PubMed ID: 29429752 [TBL] [Abstract][Full Text] [Related]
8. Defining the complement biomarker profile of C3 glomerulopathy. Zhang Y; Nester CM; Martin B; Skjoedt MO; Meyer NC; Shao D; Borsa N; Palarasah Y; Smith RJ Clin J Am Soc Nephrol; 2014 Nov; 9(11):1876-82. PubMed ID: 25341722 [TBL] [Abstract][Full Text] [Related]
9. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Le Quintrec M; Lionet A; Kandel C; Bourdon F; Gnemmi V; Colombat M; Goujon JM; Frémeaux-Bacchi V; Fakhouri F Am J Kidney Dis; 2015 Mar; 65(3):484-9. PubMed ID: 25530108 [TBL] [Abstract][Full Text] [Related]
10. Validation of a Histologic Scoring Index for C3 Glomerulopathy. Caravaca-Fontán F; Trujillo H; Alonso M; Díaz-Encarnación M; Cabello V; Ariceta G; Quintana LF; Marco H; Barros X; Ramos N; Rodríguez-Mendiola N; Cruz S; Fernández-Juárez G; Rodríguez E; de la Cerda F; Pérez de José A; López I; Fernández L; Pérez Gómez V; Ávila A; Bravo L; Lumbreras J; Allende N; Sanchez de la Nieta MD; Olea T; Melgosa M; Huerta A; Miquel R; Mon C; Fraga G; de Lorenzo A; Draibe J; González F; Shabaka A; Illescas ML; Calvo C; Oviedo V; Da Silva I; Goicoechea de Jorge E; Caravaca F; Praga M; Am J Kidney Dis; 2021 May; 77(5):684-695.e1. PubMed ID: 33359150 [TBL] [Abstract][Full Text] [Related]
11. Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. Iatropoulos P; Daina E; Curreri M; Piras R; Valoti E; Mele C; Bresin E; Gamba S; Alberti M; Breno M; Perna A; Bettoni S; Sabadini E; Murer L; Vivarelli M; Noris M; Remuzzi G; ; J Am Soc Nephrol; 2018 Jan; 29(1):283-294. PubMed ID: 29030465 [TBL] [Abstract][Full Text] [Related]
12. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Noris M; Donadelli R; Remuzzi G Pediatr Nephrol; 2019 Aug; 34(8):1311-1323. PubMed ID: 29948306 [TBL] [Abstract][Full Text] [Related]
13. Treatment of C3 glomerulopathy with complement blockers. Vivarelli M; Emma F Semin Thromb Hemost; 2014 Jun; 40(4):472-7. PubMed ID: 24799307 [TBL] [Abstract][Full Text] [Related]
14. C3 Glomerulopathy and post-infectious glomerulonephritis define a disease spectrum. Al-Ghaithi B; Chanchlani R; Riedl M; Thorner P; Licht C Pediatr Nephrol; 2016 Nov; 31(11):2079-86. PubMed ID: 27008643 [TBL] [Abstract][Full Text] [Related]
15. C3 Glomerulopathy: Pathogenesis and Treatment. Ahmad SB; Bomback AS Adv Chronic Kidney Dis; 2020 Mar; 27(2):104-110. PubMed ID: 32553242 [TBL] [Abstract][Full Text] [Related]
16. Severe active C3 glomerulonephritis triggered by immune complexes and inactivated after eculizumab therapy. Kersnik Levart T; Ferluga D; Vizjak A; Mraz J; Kojc N Diagn Pathol; 2016 Oct; 11(1):94. PubMed ID: 27717365 [TBL] [Abstract][Full Text] [Related]
17. von Willebrand factor variants in C3 glomerulopathy: A Chinese cohort study. Chen YY; Han SS; Cao Y; Yu XJ; Zhu L; Luo JC; Song WC; Yu F; Mao YH; Zhao MH Clin Immunol; 2021 Aug; 229():108794. PubMed ID: 34245915 [TBL] [Abstract][Full Text] [Related]
18. C3 glomerulopathy: the genetic and clinical findings in dense deposit disease and C3 glomerulonephritis. Xiao X; Pickering MC; Smith RJ Semin Thromb Hemost; 2014 Jun; 40(4):465-71. PubMed ID: 24799308 [TBL] [Abstract][Full Text] [Related]